OC-007 / Adlego, Karolinska Institute - LARVOL DELTA

A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations. (PubMed, Mol Ther Adv) - "Neutralizing antibody levels increased to SARS-CoV-2 Beta (1.0 and 2.0 mg groups) and Omicron XBB1.5 variants (2.0 mg group). The novel OC-007 DNA vaccine was safe, tolerable, and induced/boosted T cell responses to genetically stable proteins."

Clinical • First-in-human • Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

OpenCorona1: A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Matti Sällberg | Recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

OpenCorona1: A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Matti Sällberg | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

OpenCorona1: A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Matti Sällberg

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases